Compare Huntington Ingalls Industries Inc (HII) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs McKesson Corporation — how do they compare? Huntington Ingalls Industries Inc trades at $328.19 (market cap $12.92B), while McKesson Corporation trades at $884.82 (market cap $105.14B). The key difference: McKesson Corporation is far larger — about 8.1× Huntington Ingalls Industries Inc's market cap, and Huntington Ingalls Industries Inc pays the higher dividend (1.68%). Which is the better fit depends on your goals.
| HII | MCK | |
|---|---|---|
Market Cap | $12.92B | $105.14B |
Sector | Technology | Health |
52-Week High | $453.73 | $995.69 |
52-Week Low | $265.40 | $659.01 |
Enterprise Value | $15.84B | $111.67B |
Dividend Yield | 1.68% | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $324.38, down 1.94% on the day, with a bullish technical signal supported by moving averages and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $5.27, exceeding expectations, and secured a $2.2 billion contract for surveillance capabilities (GlobeNewsWire, August 11, 2026). Valuation ratios include a P/E of 19.53 and P/S of 0.98, indicating reasonable pricing relative to earnings and sales.
Outlook remains positive due to contract wins and margin expansion, but risks include dependence on U.S. defense spending and competitive pressures. The consensus price target of $359.67 suggests upside potential, supported by 44% buy ratings from analysts.
McKesson (MCK) trades at $889.01, up 1.04% today, with a bullish technical outlook and strong institutional support. Recent Q1 2027 earnings beat expectations, with EPS of $9.93 versus $9.56, driven by specialty drug growth and oncology performance. Revenue reached $359.05B in 2025, with net income of $3.30B, though margins remain thin. The company raised full-year guidance, reflecting operational momentum.
The stock offers upside to the consensus price target of $990.67, supported by 80% analyst buy ratings. Key risks include reliance on pharmaceutical distribution margins, regulatory pressures, and competitive threats. Earnings consistency and cost discipline are critical for sustaining valuation multiples amid healthcare sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
